Reports significant enhancements to accelerate Tigris patient enrollment including appointment of new Contract Research Organization

See the original post:
Spectral Medical Announces Fourth Quarter and Fiscal 2022 Results and Provides Corporate Update

ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference being held on March 30, 2023.

Continue reading here:
Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

OXFORD, United Kingdom, March 24, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company’s progress.

See the original post:
Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022

See the article here:
Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton

Here is the original post:
Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics

Bagsværd, Denmark, 24 March 2023 – Novo Nordisk today announced headline results from the PIONEER PLUS trial, a phase 3b, 68-week, efficacy and safety trial with once-daily oral semaglutide 25 mg and 50 mg versus 14 mg as add-on to a stable dose of 1–3 oral antidiabetic medicines in people with type 2 diabetes in need of treatment intensification. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in HbA1c at week 52 with both the 25 mg and 50 mg doses versus the 14 mg dose of oral semaglutide.

Link:
Oral semaglutide 25 mg and 50 mg demonstrate superior reductions in HbA1c and body weight versus 14 mg in people with type 2 diabetes in the PIONEER...

Regulated Information - Denominator

See the article here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLA

HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.

Read the original:
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023

First TIL Therapy BLA Submission to U.S. Food and Drug Administration First TIL Therapy BLA Submission to U.S. Food and Drug Administration

See the original post here:
Iovance Biotherapeutics Completes Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Conference call to be held on Thursday, March 30 at 8:30 a.m. ET Conference call to be held on Thursday, March 30 at 8:30 a.m. ET

See the article here:
Theriva Biologics to Reschedule Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time

Read more here:
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update

Montrouge, France, March 24, 2023

Read the rest here:
Ordinary and Extraordinary General Meeting of April 12, 2023

VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)  Marketscreener.com

Read the rest here:
VOR BIOPHARMA INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) - Marketscreener.com

MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)  Marketscreener.com

Read the original post:
MAGENTA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K) - Marketscreener.com

BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100  Marketscreener.com

Read more:
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100 - Marketscreener.com

BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected patient population  Marketscreener.com

Visit link:
BioSenic delivers a new post-hoc analysis of its Phase III JTA-004 trial on knee osteo-arthritis with positive action on the most severely affected...

Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in  EIN News

Read the original post:
Regenerative Therapies Market is Set to Grow at a CAGR of 8.7% by 2033, Propelled by Advancements in - EIN News

Company to host conference call March 16, 2023, at 4:30 PM EDT Company to host conference call March 16, 2023, at 4:30 PM EDT

More here:
Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2022 and Provides Corporate Update

Announced SC291 IND clearance with goal to report initial clinical data this year

Originally posted here:
Sana Biotechnology Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET

See more here:
Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates